BioSpace

Your source for biopharma news and jobs

[BioSpace @biospace]

Silence Therapeutics’ lead siRNA asset for the rare blood cancer polycythemia vera has been earning analyst raves in a tight race to challenge Takeda in a potential $2 billion market.

https://t.co/tQ1oYopOJG

[BioSpace @biospace]

AbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster can be outdone.

https://t.co/4FEojQYDLZ

[BioSpace @biospace]

Roche is offering $400 million upfront and over $15 billion in biobucks to team up with Hansoh Pharmaceutical in hopes of developing a portfolio of new antibody-drug conjugates using the latter’s in-house tech.

https://t.co/Uf0cXaXi5Q

[BioSpace @biospace]

The new policy signals an escalation by the Chinese government on biopharma deals but is unlikely to have a major impact given that the vast majority of foreign interest in Chinese biotech comes in the form of licensing agreements.

https://t.co/TMNmOeoGQB

[BioSpace @biospace]

Novartis will continue to study Fabhalta in other indications, with late-stage studies in two rare diseases—atypical haemolytic uraemic syndrome and generalized myasthenia gravis—expected to read out later this year and next year, respectively.

https://t.co/5vkA1LqTLb

[BioSpace @biospace]

Disc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria were able to spend in the sun and artificial light.

https://t.co/sCIPNctOTk

[BioSpace @biospace]

In the wake of a successful IPO and strong stock growth throughout the year, Veradermics now has late-stage data to support a regulatory package for its hair loss pill.

https://t.co/ikFE006uLl

[BioSpace @biospace]

High-quality cytokines for organoid growth, differentiation, and expansion

https://t.co/PwLoj7Dw2h

[BioSpace @biospace]

At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on Merck and Moderna’s personalized cancer vaccine, Summit and Akeso’s PD-1xVEGF bispecific therapy, and many antibody-drug conjugates.

https://t.co/lVKAwFDcxy

[BioSpace @biospace]

While GLP-1 medicines are now synonymous with weight loss, one expert thinks amylin would have been the go-to target if biopharma had focused on the blockbuster indication 10 years ago. A new wave of therapies explores this potentially gentler mechanism.

https://t.co/C8paoqyCl6

[BioSpace @biospace]

As trispecifics, cell engagers and other complex formats multiply, drug developers are seeking discovery and engineering partners to help navigate an expanding universe of molecular possibilities.

https://t.co/FiFFAOjEuG

[BioSpace @biospace]

Estuary Biotherapeutics is seeking to address the root cause of autosomal dominant polycystic kidney disease with two gene therapy programs based on science from Yale.

https://t.co/TIGbsY9dJt

[BioSpace @biospace]

City Therapeutics will join a slew of biotechs that have entered the public markets this year, with a $200 million raise that landed above expectations.

https://t.co/RrkISRft59

[BioSpace @biospace]

Inconsistent reporting at a Pennsylvania site affected microbiological analyses of components and drug products that analytical testing service provider Eurofins ran for customers.

https://t.co/vh1oFYJ1Pe

[BioSpace @biospace]

The sixth cycle of OrbiMed’s Asia Partners fund included one with more than $1 billion earmarked for life science companies based on the Eastern continent.

https://t.co/yN0HSae7A1

[BioSpace @biospace]

After years of quiet maturation, new approach methodologies and emerging clinical success for cell therapies are fueling parallel momentum for induced pluripotent stem cells.

https://t.co/7iKGtrJ5bV

[BioSpace @biospace]

AstraZeneca will tap AI-focused insitro to find new targets for metabolic dysfunction-associated steatohepatitis and cardiomyopathies, following the Phase 3 failure of its Ionis-partnered Wainua in transthyretin-mediated amyloid cardiomyopathy.

https://t.co/qLbIUeqMju

[BioSpace @biospace]

Less than a month after announcing that it would shutter its German manufacturing facility and slash about 650 jobs there, GSK is cutting more than 1,200 roles in Belgium as part of its $2.5 billion global restructuring.

https://t.co/JRyB7nFgL4

[BioSpace @biospace]

Following several recent initiatives, the FDA’s newest rare disease framework sets out to standardize the agency’s approach to scientific evidence and bring rare disease therapies to patients faster.

https://t.co/1CqrR7o4Vi

[BioSpace @biospace]

A new biotech co-founded by Paul Stoffels has formed to take on the CAR T cell assets of Galapagos almost a year after the company—now known as Lakefront Biotherapeutics—abandoned them.

https://t.co/5KQFnKSLLX